Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $0.41, $0.44 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $151.81 million versus the consensus estimate of $112.72 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.